Nexavar — Cigna
Renal cell carcinoma that is advanced
Preferred products
- generic sorafenib tablets
Initial criteria
- Patient meets the standard Oncology – Sorafenib Prior Authorization Policy criteria; AND
- Patient has tried generic sorafenib tablets [documentation required]; AND
- Patient cannot continue to use the Preferred medication due to a formulation difference in the inactive ingredient(s) (e.g., difference in dyes, fillers, preservatives) which, per the prescriber, would result in a significant allergy or serious adverse reaction [documentation required]
Approval duration
1 year